Pfizer’s Nyvepria (pegfilgrastim-apgf) 6mg pre-filled syringe formulation has been approved by the US Food and Drug Administration but will remain off the market for now, as the company continues to grapple with Amgen over intellectual property shielding its Neulasta (pegfilgrastim) reference product.
Amgen sued Pfizer in February this year, alleging infringement of US patent 8,273,707 directed at methods of protein...






